
Sanofi appoints an Ebola response co-ordinator
pharmafile | November 19, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Ebola, Sanofi, gary nobel
Former director of the NIH Vaccine Research Center Dr Gary Nabel has been hired by Sanofi to spearhead its contribution towards the ‘global fight against Ebola’.
Nabel who is the firm’s chief scientific officer and senior VP, will be identifying how Sanofi can advance countermeasures to contain the current outbreak, and “prioritise and foster opportunities to develop novel treatments for the future”.
“Given his past experience in public health epidemics as director of the NIH Vaccine Research Center and his leadership in developing an Ebola vaccine at NIH, Dr Nabel is uniquely qualified for this position,” says Dr Elias Zerhouni, president of Sanofi Global R&D.
“Dr Nabel is working with other organisations, including providing guidance to researchers based on the company’s extensive experience in vaccine and drug development, to determine how Sanofi can assist in making progress with this global challenge.”
Nabel adds: “Working with our colleagues across the industry, Sanofi is helping to find ways to advance medicines to prevent or treat Ebola virus infection. We are also sharing our scientific, medical, regulatory, and manufacturing expertise with the World Health Organization, government and non-governmental organisations – public and private – in an effort to contain this epidemic.”
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






